Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tomohiro Asahi is active.

Publication


Featured researches published by Tomohiro Asahi.


Diabetes Care | 2011

Impaired Glucose Tolerance, but Not Impaired Fasting Glucose, Underlies Left Ventricular Diastolic Dysfunction

Michio Shimabukuro; Namio Higa; Tomohiro Asahi; Ken Yamakawa; Yoshito Oshiro; Moritake Higa; Hiroaki Masuzaki

OBJECTIVE Glucose intolerance is recognized as a predictor of congestive heart failure (CHF). However, the association of postprandial hyperglycemia or fasting hyperglycemia with CHF has not been clarified. We determined the impact of the total spectrum of glucose abnormalities on left ventricular (LV) geometry and diastolic function. RESEARCH DESIGN AND METHODS Two hundred and eighty-seven Japanese subjects who visited the university hospital to be checked for glucose intolerance or known type 2 diabetes were consecutively recruited. Participants underwent an oral glucose tolerance test if they had no history of diabetes, and LV geometry and LV systolic and diastolic function were analyzed by Doppler echocardiography. RESULTS The frequency of LV diastolic dysfunction in subjects with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), newly detected diabetes, and known diabetes were 13, 22, 50, 51, and 61%, respectively (χ2 = 54.2, P < 0.0001). IGT was a predictor for LV diastolic dysfunction after adjusting for age, sex, systolic blood pressure, and heart rate (odds ratio 3.43 [95% CI 1.09–11.2]), but IFG was not (0.49 [0.06–3.08]). IGT was a predictor after adjusting for established CHF risk factors but was no longer significant after adjusting for BMI and homeostasis model assessment of insulin resistance. CONCLUSIONS In this hospital-based registry of subjects without CHF, the prevalence of LV diastolic dysfunction was higher in subjects with IGT but not in those with IFG. Results suggest that IGT, as well as newly detected and known diabetes, could be linked to an increased risk of cardiovascular events, partly through LV diastolic dysfunction.


Thyroid | 2001

Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats.

Tomohiro Asahi; Michio Shimabukuro; Yoshito Oshiro; Hisashi Yoshida; Nobuyuki Takasu

We evaluated the effects of hyperthyroidism on cardiac structural changes and postischemic myocardial function, and also studied how an angiotensin-converting enzyme (ACE) inhibitor, cilazapril, can alter these changes. Hyperthyroidism was induced by daily intraperitoneal injection of thyroxine (T4) (600 microg/kg) with or without cilazapril (10 mg/kg per day, orally), and control rats were given by vehicle. After 2 weeks of treatment, T4-treated rats showed increases in blood pressure and heart weight to body weight ratio (HW:BW). Cilazapril decreased blood pressure to control values and reduced HW:BW. In the isolated working heart preparation, T4-treated rats showed a poor postischemic recovery of left ventricular pressure-rate product (14% of baseline at 30 minutes of reperfusion vs. vehicle 85%) and cardiac work (6% vs. 71%). Cilazapril recovered both values to 49% and 43%. Propranolol (500 mg/L in drinking water) decreased blood pressure to the same extent as cilazapril in hyperthyroid rats, but changed neither HW:BW nor the postischemic myocardial dysfunction. Percent recovery of cardiac work was inversely well correlated with HW:BW (R2 = 0.998, p < 0.001). Results indicate that T4-induced cardiac hypertrophy enhances postischemic cardiac dysfunction. Results also indicate renin-angiotensin system (RAS), but not sympathetic nerve activation, is involved in cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats.


Diabetes, Obesity and Metabolism | 2007

Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients

Michio Shimabukuro; Namio Higa; Yoshito Oshiro; Tomohiro Asahi; Nobuyuki Takasu

Aim:  Left ventricular (LV) diastolic dysfunction has been reported to be prevalent in diabetic subjects, but this recognition could often be missed. We evaluated prevalence of LV diastolic dysfunction and diagnostic utility of brain‐natriuretic peptide (BNP) in asymptomatic patients with type 2 diabetes mellitus.


Life Sciences | 2001

Triiodothyronine concomitantly inhibits calcium overload and postischemic myocardial stunning in diabetic rats

Yoshito Oshiro; Michio Shimabukuro; Nobuyuki Takasu; Tomohiro Asahi; Ichiro Komiya; Hisashi Yoshida

Acute effects of triiodothyronine (T3) on postischemic myocardial stunning and intracellular Ca2+ contents were studied in the isolated working hearts of streptozotocin-induced diabetic rats and age-matched controls. After two weeks of diabetes, serum T3 and T4 levels were decreased to 62.5% and 33.9% of control values. Basal preischemic cardiac performance did not differ between diabetic and control rats. In contrast, during reperfusion after 20-min ischemia, diabetic rats exhibited an impaired recovery of heart rate (at 30-min reperfusion 57.5% of baseline vs. control 88.5%), left ventricular (LV) systolic pressure (44.1% vs. 89.5%), and cardiac work (23.1% vs. 66.0%). When 1 and 100 nM T3 was added before ischemia, heart rate was recovered to 77.2% and 81.8% of baseline, LV systolic pressure to 68.3% and 81.9%, and cardiac work to 50.8% and 59.0%, respectively. Diabetic rat hearts showed a higher Ca2+ content in the basal state and a further increase after reperfusion (4.96+/-1.17 vs. control 3.78+/-0.48 micromol/g, p<0.01). In diabetic hearts, H+ release was decreased after reperfusion (5.24+/-2.21 vs. 8.70+/-1.41 mmol/min/g, p<0.05). T3 administration caused a decrease in the postischemic Ca2+ accumulation (lnM T3 4.66+/-0.41 and 100 nM T3 3.58+/-0.36) and recovered the H+ release (lnM T3 16.2+/-3.9 and 100 nM T3 11.6+/-0.9). T3 did not alter myocardial O2 consumption. Results suggest that diabetic rat hearts are vulnerable to postischemic stunning, and T3 protects the myocardial stunning possibly via inhibiting Ca2+ overload.


Cardiology Research and Practice | 2012

Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients

Ken Yamakawa; Michio Shimabukuro; Namio Higa; Tomohiro Asahi; Kageyuki Ohba; Osamu Arasaki; Moritake Higa; Yoshito Oshiro; Hisashi Yoshida; Tohru Higa; Taro Saito; Shinichiro Ueda; Hiroaki Masuzaki; Masataka Sata

We investigated the effects of purified eicosapentaenoic acid (EPA) on vascular endothelial function and free fatty acid composition in Japanese hyperlipidemic subjects. In subjects with hyperlipidemia (total cholesterol ≥220 mg/dL and/or triglycerides ≥150 mg/dL), lipid profile and forearm blood flow (FBF) during reactive hyperemia were determined before and 3 months after supplementation with 1800 mg/day EPA. Peak FBF during reactive hyperemia was lower in the hyperlipidemic group than the normolipidemic group. EPA supplementation did not change serum levels of total, HDL, or LDL cholesterol, apolipoproteins, remnant-like particle (RLP) cholesterol, RLP triglycerides, or malondialdehyde-modified LDL cholesterol. EPA supplementation did not change total free fatty acid levels in serum, but changed the fatty acid composition, with increased EPA and decreased linoleic acid, γ-linolenic acid, and dihomo-γ-linolenic acid. EPA supplementation recovered peak FBF after 3 months. Peak FBF recovery was correlated positively with EPA and EPA/arachidonic acid levels and correlated inversely with dihomo-γ-linolenic acid. EPA supplementation restores endothelium-dependent vasodilatation in hyperlipidemic patients despite having no effect on serum cholesterol and triglyceride patterns. These results suggest that EPA supplementation may improve vascular function at least partly via changes in fatty acid composition.


Circulation | 2016

Respiratory Collapse of the Inferior Vena Cava Reflects Volume Shift and Subsequent Fluid Refill in Acute Heart Failure Syndrome.

Tomohiro Asahi; Marohito Nakata; Namio Higa; Mamoru Manita; Kazuhiko Tabata; Michio Shimabukuro

BACKGROUND Fluid redistribution rather than fluid accumulation plays an important role in the development of acute heart failure (HF) syndrome. Patients with fluid redistribution develop acute HF without prominent volume overload. We investigated volume status by measuring the diameter of the inferior vena cava (IVC) and examining variations in hemoglobin and hematocrit. METHODSANDRESULTS Seventy-four consecutive patients admitted for acute HF syndrome were analyzed. Blood tests and measurement of IVC diameter after stabilization of respiratory distress were performed on admission and were repeated after 24 h. IVC collapsibility index (IVC-CI) was calculated as (maximum IVC-minimum IVC)/maximum IVC. According to the initial IVC-CI, the patients were divided into the collapse group (IVC-CI ≥0.5: n=34) and the non-collapse group (IVC-CI <0.5: n=40). Initial blood pressure was higher in the collapse group (P<0.001). Although 24-h urine volume did not differ between the groups, hemoglobin (P<0.001) and hematocrit (P<0.001) decreased significantly in the collapse group but not in the non-collapse group after 24 h. Furthermore, IVC-CI significantly decreased in the collapse group after 24 h (P=0.003). CONCLUSIONS In acute HF syndrome, IVC-CI ≥0.5 on admission suggests a volume shift from the central vein into the pulmonary vasculature. Fluid refill occurs within 24 h after admission. This observation could be helpful in selecting strategies for diuretic use. (Circ J 2016; 80: 1171-1177).


The Journal of Clinical Endocrinology and Metabolism | 2003

Hypoadiponectinemia Is Closely Linked to Endothelial Dysfunction in Man

Michio Shimabukuro; Namio Higa; Tomohiro Asahi; Yoshito Oshiro; Nobuyuki Takasu; Tatsuya Tagawa; Shinichiro Ueda; Iichiro Shimomura; Tohru Funahashi; Yuji Matsuzawa


Metabolism-clinical and Experimental | 2004

Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction

Michio Shimabukuro; Namio Higa; Tomohiro Asahi; Yoshito Oshiro; Nobuyuki Takasu


Japanese Circulation Journal-english Edition | 2009

PE-109 Evaluation of Postsystolic Shortening Assessed by Automated Function Imaging in Patients with Unstable Angina(PE019,Echo/Doppler (New Technology) (I),Poster Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)

Tomohiro Asahi; Namio Higa; Tami Mashidori; Kazuhiko Tabata; Eikei Sakihara


Japanese Circulation Journal-english Edition | 2008

PJ-846 Diagnostic utility of brain-natriuretic peptide for left ventriculardiastolic dysfunction in asymptomatic type 2 diabetic patients(Diabetes / Obesity / Metabolic syndrome(16)(H),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)

Michio Shimabukuro; Namio Higa; Ichiro Chinen; Ken Yamakawa; Tomohiro Asahi; Nobuyuki Takasu

Collaboration


Dive into the Tomohiro Asahi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nobuyuki Takasu

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Namio Higa

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Yoshito Oshiro

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Hisashi Yoshida

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Ken Yamakawa

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Satoshi Higa

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shinichiro Ueda

University of the Ryukyus

View shared research outputs
Top Co-Authors

Avatar

Sugako Ishigaki

University of the Ryukyus

View shared research outputs
Researchain Logo
Decentralizing Knowledge